Cabaletta Bio's and Gracell's stock plunges as FDA probes risks of CAR-T therapy

Shares of small biotech companies involved in CAR-T therapies plunged Tuesday as the FDA said it was investigating potential cancer risks.

Related Keywords

,Gracell Biotechnologies Inc ,Drug Administration ,Cabaletta Bio Inc ,Cabaletta Bio ,Gracell Biotechnologies ,Article Normal ,Biotechnology Services ,Pharmaceuticals ,Healthcare Life Sciences ,Aerospace Defense ,Biopharmaceuticals ,Biological Therapy ,Defense Equipment Products ,Industrial Goods ,Healthcare Provision ,Regulation Government Policy ,Analysts Amp 39 Comments Recommendations ,Ownership Changes ,Acquisitions Mergers Shareholdings ,New Products Services ,Corporate Actions ,Product Service Approvals ,Corporate Industrial News ,Products Services ,Cancer ,Political General News ,Health ,Medical Conditions ,Content Types ,Factiva Filters ,C Amp Ampe Exclusion Filter ,C Amp Ampe Industry News Filter ,Caba ,Gracell Biotechnologies Inc Adr ,Grcl ,Novartis Ag Adr ,Nvs ,Gilead Sciences Inc ,Gild ,Regulation ,Government Policy ,Analysts Amp 39 Comments ,Recommendations ,Acquisitions ,Mergers ,Shareholdings ,New Products ,Services ,Product ,Service Approvals ,Corporate ,Industrial News ,Products ,Political ,General News ,Healthcare ,Life Sciences ,Aerospace ,Defense ,Defense Equipment ,